Biocon Ltd was quoted at Rs 409.6, up 1.78% on the day as at 12:49 NSE IST. The stock has gained 5.04% over the past year, compared with NIFTY’s gain of 56.03% and the Nifty Pharma index’s gain of 40.58%. The benchmark NIFTY was up about 0.28 percent on the day at 15,784.25. …

Why is Biocon stock falling?

Biocon’s share price is It fell more than 2% intraday on July 6. . . Biocon is in the spotlight for the wrong reasons, as market regulator Sebi has restricted an officer of Biocon Ltd from accessing the securities market for three months and fined him for violating insider trading norms.

Will Biocon go up?

Will Biocon share price go up/up/up? yes. BIOCON stock price can go from 367.550 INR to 416.218 INR in one year.

Is Biocon Overrated?

Biocon’s price/FCF ratio among its peers is negative and below the industry average. This shows that Biocon Stocks are highly overvalued.

Does Biocon have no debt?

The company has virtually no debt. The company has a healthy interest coverage ratio of 898. The company has a healthy liquidity position with a current ratio of 3.94. The company’s high promoter holds 60.64% of the shares.

Why Biocon Ltd is a good stock to buy right now? Good Chance Hemant Jain | (Hindi)

25 related questions found

Who is Biocon’s CEO?

Siddhartha Mittal is the Managing Director and Chief Executive Officer of Biocon Ltd. He joined Biocon in May 2013 and served as President and Chief Financial Officer from August 2014 to November 2019.

Is Cipla a debt free company?

‘When we think about how risky a company is, we always like to look at its use of debt, because debt overload can lead to bankruptcy. We can see Cipla Limited (NSE:CIPLA) does use debt in its business.

What does Biocon do today?

Biocon Limited is an Indian biopharmaceutical company headquartered in Bangalore, India, founded by Kiran Mazumdar-Shaw. …it also produces Novel biologics, as well as biosimilar insulins and antibodiessold as a branded formula in India.

What is a stock stop loss?

A stop loss order is Place an order to a broker to buy or sell a specific stock once the stock reaches a specific price. Stop Loss is designed to limit an investor’s loss on a security position. For example, placing a stop loss order 10% below the price at which you bought the stock will limit your losses to 10%.

Is Laurus Labs Overpriced?

PB and Industry: LAURUSLABS is based on overestimation Its PB ratio (13.7x) compared to the Indian pharma industry average (3x).

What is the future of Laurus Labs?

Laurus Labs Ltd.’s quote on September 22, 2021 is equal to INR 623.850. According to our forecast, long-term rise is expected, « Laurus Labs Ltd » share price forecast 2026-09-18 is 994.584 INR. Investment for 5 years, the expected income is about +59.43%.

Is Laurus Labs Underrated?

P/E ratio

Private Equity and Industry: 540222 Value is not high Based on its P/E ratio (35.8x) compared to the Indian pharma industry average (26.8x). P/E Ratio vs Market: 540222 has a poor P/E ratio (35.8x) compared to the Indian market (23.4x).

Does Sun Pharma have no debt?

Debt Level: SUNPHARMA’s debt-to-equity ratio (6.8%) is considered satisfactory. Debt reduction: SUNPHARMA’s debt-to-equity ratio has fallen from 23.2% to 6.8% over the past 5 years.Debt Coverage: SUNPHARMA’s debt is good coverage Through operating cash flow (184.6%).

What is the largest pharmaceutical company in the world?

1. Roche $49.50. Roche retains its position as the largest company by sales of pharmaceuticals in 2021. Roche has more than 90,000 employees and is headquartered in Basel, Switzerland, at the forefront of oncology, immunology, infectious diseases, ophthalmology and neuroscience.

How is the TTM P/E ratio calculated?

Types of P/E Ratios

1. Last Twelve Month (TTM) PE: TTM PE is the current share price divided by the EPS for the most recent 4 quarters. …
2. Forward P/E Ratio: The forward P/E ratio is the current share price divided by the projected earnings per share for the next 4 quarters.

Is Kiran Mazumdar-Shaw Bengali?

Kiran Mazumdar was born on March 23, 1953 in Bangalore, Karnataka. Gujarati parents.

Who is the owner of a biotech company?

Krishna Ella is the Chairman and Managing Director of Bharat Biotech International Ltd, which was established in 1996. Dr. Ella is a University Gold Medalist who worked as a researcher at the Medical University of South Carolina in Charleston after earning her Ph.D.